Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Han, S., Czerwinski, R.M., Caspers, N.L., Limburg, D.C., Ding, W., Wang, H., Ohren, J.F., Rajamohan, F., McLellan, T.J., Unwalla, R., Choi, C., Parikh, M.D., Seth, N., Edmonds, J., Phillips, C., Shakya, S., Li, X., Spaulding, V., Hughes, S., Cook, A., Robinson, C., Mathias, J.P., Navratilova, I., Medley, Q.G., Anderson, D.R., Kurumbail, R.G., Aulabaugh, A.(2014) Biochem J 460: 211-222
- PubMed: 24593284 
- DOI: 10.1042/BJ20131139
- Primary Citation of Related Structures:  
4M0Y, 4M0Z, 4M12, 4M13, 4M14, 4M15 - PubMed Abstract: 
ITK (interleukin-2-inducible T-cell kinase) is a critical component of signal transduction in T-cells and has a well-validated role in their proliferation, cytokine release and chemotaxis. ITK is an attractive target for the treatment of T-cell-mediated inflammatory diseases ...